[准备维捷辛白胺纳米颗粒及其药理动力学研究]
Xue Zhang1, Qiang Wang1, Jian-Quan Pan1
1School of Pharmacy, Anhui University of Chinese Medicine Hefei 230012, China.
概括
这项研究开发了维捷辛专纳米颗粒 (VT-BSA-NPs) 以提高维捷辛 (VT) 的生物可用性. 这种新型纳米粒子在体内改善了药理动力学特性,有效地增加了静脉瘤的吸收.
科学领域:
- 纳米技术 纳米技术
- 材料科学 材料科学 材料科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 维素 (VT) 具有较差的水溶性,限制了其体内生物可用性.
- 开发有效的交付系统对于增强VT的治疗潜力至关重要.
研究的目的:
- 为改善静脉道输送准备和特征化维特辛专纳米颗粒 (VT-BSA-NP).
- 评估VT-BSA-NP的物理化学性质,体外释放和体内药理动力学.
主要方法:
- 维素 (VT) 微粉末通过抗溶剂结晶制备.
- 使用脱溶-交联固化方法合成的VT-BSA-NP.
- 特性包括颗粒大小,PDI,Zeta潜力,封装效率,形态,体外释放,以及在老鼠中的LC-MS/MS药物动力学分析.
主要成果:
- 微型VT粉末的颗粒大小为187.13±7.15nm,形状为球体.
- 优化的VT-BSA-NP显示平均粒子大小为124.33±0.47nm,PDI为0.184±0.012,Zeta电位为-48.83±2.20mV,以及83.43%±0.39%的封装效率.
- 在体外,VT-BSA-NP表现为持续的体外释放,在体内与自由的VT相比,体内显著增加了AUC,MRT和t_(1/2).
结论:
- 成功制备了具有有利的物理化学性质和封装效率的VT-BSA-NP.
- 这些纳米颗粒通过持续释放和增强的药理动力学参数有效地提高了维特辛的生物可用性.
- VT-BSA-NP代表了一种有前途的纳米载体,可以增强维捷克辛的治疗效果.
相关概念视频
01:16Methods for Studying Drug Absorption: In vitro
In vitro experiments are crucial for understanding the transport and absorption of drugs through biological materials. These studies employ varied methods such as the diffusion cell method, the everted sac technique, and the everted ring technique.
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:20Drug Product Performance: In Vitro–In Vivo Correlation
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
01:20Estimation of k and VD of Aminoglycosides
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...